ISLAMABAD — Technology conglomerate Huawei has made a significant foray into the medical device sector by unveiling its inaugural continuous glucose monitor (CGM), the Sense G1, according to reporting by the Newsbeat Desk. Designed to attach discreetly to the upper arm, the compact, round device monitors user glucose levels continuously day and night, eliminating the necessity for traditional, painful finger pricks for every individual reading.
Citing details published by Mydrivers, dispatches indicate that the sensor utilizes a flexible subcutaneous probe alongside an enzyme called glucose oxidase and electrodes to measure glucose concentrations within interstitial fluid. Each single-user device operates without manual calibration and can transmit real-time alerts whenever readings deviate from established target ranges, with data accessible on compatible smartphones or smartwatches for up to 16 days.
Regarding technical performance and precision, reports note that a tipster cited by Mydrivers estimated the mean absolute relative difference (MARD) of the Sense G1 to be below 10 percent, while observing a potential reading lag of five to 15 minutes compared to actual blood glucose fluctuations. However, these specific performance metrics remain unconfirmed by Huawei itself, even as the hardware establishes a new operational precedent for the consumer electronics giant.
The regulatory landscape for the product cleared a major hurdle when China’s National Medical Products Administration officially registered the Sense G1 as a Class III medical device, as highlighted by the Newsbeat Desk. Representing China's highest risk category—a classification typically reserved for high-stakes interventions such as artificial joints and cardiac stents—this milestone marks Huawei's maiden Class III regulatory clearance within its consumer division and paves the way for future medical technology deployments.